Edition:
United States

Vertex Pharmaceuticals Inc (VRTX.O)

VRTX.O on Nasdaq

148.13USD
18 Aug 2017
Change (% chg)

$-0.41 (-0.28%)
Prev Close
$148.54
Open
$147.65
Day's High
$150.11
Day's Low
$147.18
Volume
887,138
Avg. Vol
1,922,217
52-wk High
$167.85
52-wk Low
$71.46

Latest Key Developments (Source: Significant Developments)

Vertex Pharmaceuticals appoints Ian Smith COO and CFO
Friday, 2 Dec 2016 09:21am EST 

Vertex Pharmaceuticals Inc : Vertex Pharmaceuticals -effective January 1, 2017, have appointed Ian Smith EVP - chief operating officer and chief financial officer . On Nov 30, term of CEO Jeffrey Leiden's employment agreement was extended through March 31, 2020 .Aslo, Leiden's cash severance benefit was reduced from 200 pct and target bonus to 100 pct of sum of base salary.  Full Article

Vertex Pharma: Amended and expanded agreement with Cystic Fibrosis Foundation Therapeutics
Friday, 14 Oct 2016 06:38am EDT 

Vertex Pharmaceuticals Inc : Vertex Pharma - on oct 13 amended and expanded research, development and commercialization agreement with cystic fibrosis foundation therapeutics inc . Vertex Pharma - amendment provides for upfront program award from cfft to us of $75.0 million,development funding from cfft to us of upto $6.0 million annually . Vertex Pharmaceuticals Inc- pursuant to amendment , co will continue to pay royalties ranging from low single digits to mid-single digits .Vertex Pharma-entered into data license deal with Cystic Fibrosis Foundation, co will pay for continuing access to data from CFF's patient registry.  Full Article

Vertex enrollment complete in Phase 3 study in people with two copies of F508DEL mutation
Monday, 15 Aug 2016 04:05pm EDT 

Vertex : Provides update on ongoing phase 3 program For VX-661 in combination with ivacaftor for the treatment of cystic fibrosis . Enrollment complete in phase 3 study in people with two copies of F508DEL mutation . Enrollment expected to be completed in September in phase 3 study in people with one F508DEL mutation, one residual function mutation .Plans to submit new drug application (NDA) to FDA for vx-661 in combination with ivacaftor in second half of 2017.  Full Article

Vertex Pharmaceuticals says reiterates 2016 guidance
Wednesday, 27 Jul 2016 04:16pm EDT 

Vertex Pharmaceuticals Inc : Vertex pharmaceuticals inc says reiterates 2016 guidance for orkambi product revenues of $1.0 to $1.1 billion . Gaap research and development and sg&a expenses . Vertex reports second quarter 2016 financial results . Q2 non-gaap earnings per share $0.24 . Q2 gaap loss per share $0.26 . Q2 earnings per share view $0.21 -- Thomson Reuters I/B/E/S .Vertex pharmaceuticals inc says reiterates 2016 guidance for kalydeco product revenues of $685 to $705 million.  Full Article

Vertex Pharmaceuticals and Moderna collaborate to discover and develop MRNA Therapeutics for cystic fibrosis
Wednesday, 6 Jul 2016 08:14am EDT 

Vertex Pharmaceuticals Inc : Vertex and Moderna establish exclusive collaboration to discover and develop mrna therapeutics(tm) for cystic fibrosis . Vertex will also pay Moderna future development and regulatory milestones of up to $275 million . Vertex Pharmaceuticals says $275 million payment, including $220 million in reimbursement milestones, as well as tiered royalty payments on future sales . Vertex Pharmaceuticals Inc says Moderna to receive $40 million upfront, made up of a $20 million cash payment and a $20 million convertible note investment . Vertex and Moderna will conduct exclusive research, development and commercialization activities to advance mrna therapeutics . Will lead all preclinical, development and commercialization activities associated with advancement of mrna therapeutics .Will fund all expenses related to collaboration.  Full Article

Vertex Pharma says target review date of Sept. 30 set for FDA's decision on application
Tuesday, 31 May 2016 07:58am EDT 

Vertex Pharmaceuticals Inc : Target review date of september 30, 2016 set for fda's decision on application .u.s. Fda accepts for priority review supplemental new drug application for the use of orkambi® (lumacaftor/ivacaftor) in children with cystic fibrosis ages 6 to 11 who have two copies of the f508del mutation.  Full Article

Spero Therapeutics to acquire worldwide rights to Vertex's VXC-486/VXC-100
Wednesday, 25 May 2016 08:00am EDT 

Spero Therapeutics LLC : Has entered into an agreement with Vertex Pharmaceuticals . Deal to acquire worldwide rights to VXC-486/VXC-100 and a portfolio of innovative antibacterial compounds . Under terms of agreement, Spero will make an upfront payment to Vertex for portfolio rights . Under terms of agreement, Spero will assume responsibility for drug development and bringing compounds to market .Vertex will be eligible to get future devpt,commercial milestones, royalties on any therapeutic products resulting from agreement.  Full Article

Vertex receives Australian approval for Orkambi
Tuesday, 8 Mar 2016 03:50pm EST 

Vertex Pharmaceuticals Inc:Receives Australian approval for Orkambi® (lumacaftor/ivacaftor), the first medicine to treat the underlying cause of cystic fibrosis in people ages 12 and older with two copies of the f508del mutation.Says Therapeutic Goods Administration (TGA) of Australia has approved Orkamb.  Full Article

Vertex Pharmaceuticals Inc and CRISPR Therapeutics establish collaboration to use CRISPR-Cas9 gene editing technology to discover and develop new treatments for genetic diseases
Monday, 26 Oct 2015 08:00am EDT 

Vertex Pharmaceuticals Inc:Says Co and CRISPR therapeutics establish collaboration to use crispr-cas9 gene editing technology.Says will pay future milestones of up to $420 million as well as royalty payments on future sales.Says will pay CRISPR $75 million in cash as part of its up-front commitment.Says companies establish four-year research collaboration and CRISPR to receive $105 million up-front payment.Says will also provide a $30 million investment in CRISPR, which is a private company.CRISPR is also eligible to receive future development, regulatory and sales milestones and royalty payments on future sales.Says Vertex and CRISPR will jointly use the CRISPR-cas9 technology to discover and develop potential new treatments.Says discovery activities will be conducted primarily by CRISPR, and the related expenses will be fully funded by Vertex.Says discovery activities will be conducted primarily by CRISPR, and the related expenses will be fully funded by Vertex.  Full Article

Vertex Pharmaceuticals Inc announces progress in development efforts to treat the cause of cystic fibrosis in the vast majority of people with disease
Thursday, 8 Oct 2015 09:00am EDT 

VertexVertex Pharmaceuticals Inc:Announces significant progress in its development efforts to treat the cause of cystic fibrosis in the vast majority of people with the disease.Says is advancing two next-generation correctors from its research program into clinical development.Plans to initiate phase 2 studies in people with cf evaluating vx-440 or vx-152 in combination with vx-661/ivacaftor in second half of 2016.Says studies of a triple combination planned for the second half of 2016.  Full Article

BRIEF-FDA approves Kalydeco(Ivacaftor) for more than 600 people ages 2 and older with Cystic Fibrosis who have certain residual function mutations

* FDA approves Kalydeco (Ivacaftor) for more than 600 people ages 2 and older with Cystic Fibrosis who have certain residual function mutations